BXRX
Baudax Bio, Inc. [BXRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BXRX Stock Summary
In the News
BXRX Financial details
Company Rating
-
Market Cap
950.33K
Income
-7.15M
Revenue
326K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.04
Forward P/E
-
PEG
0
P/S
4.32
P/B
-0.03
P/C
-
P/FCF
-0.1
Quick Ratio
0.02
Current Ratio
0.07
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.54
EPS next Y
-
EPS next Q
-
EPS this Y
-50.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-84.11%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-35%
ROE
55%
ROC
-14.43%
Gross Margin
-1539%
Oper. Margin
-6782%
Profit Margin
-2194%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0137-3.4699
52W High
-
52W Low
-
RSI
50
Rel Volume
0.73
Avg Volume
424.85K
Volume
310.87K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.583
-
-
Volatility
0.07%, 0.07%
Prev Close
-88.3%
Price
0.0218
Change
-
Company Profile
- Volume Average 424.85K
- Market Capitalization 950.33K
- Employee 9
- CEO Dr. Geraldine A. Henwood Ph.D.
- Headquarters Malvern,PA,US
- IPO Date 2019-11-14
-
Website
https://www.baudaxbio.com 
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
